[Tea consumption and cancer: a Mendelian randomization study].

Objective: A Mendelian randomization (MR) analysis was performed to assess the relationship between tea consumption and cancer. Methods: There were 100 639 participants with the information of gene sequencing of whole genome in the China Kadoorie Biobank. After excluding those with cancer at baseline survey, a total of 100 218 participants were included in this study. The baseline information about tea consumption were analyzed, including daily tea consumption or not, cups of daily tea consumption, and grams of daily tea consumption. We used the two-stage least square method to evaluate the associations between three tea consumption variables and incidence of cancer and some subtypes, including stomach cancer, liver and intrahepatic bile ducts cancer, colorectal cancer, tracheobronchial and lung cancer, and female breast cancer. Multivariable MR and analysis only among nondrinkers were used to control the impact of alcohol consumption. Sensitivity analyses were also performed, including inverse variance weighting, weighted median, and MR-Egger. Results: We used 54, 42, and 28 SNPs to construct non-weighted genetic risk scores as instrumental variables for daily tea consumption or not, cups of daily tea consumption, and grams of daily tea consumption, respectively. During an average of (11.4±3.0) years of follow-up, 6 886 cases of cancer were recorded. After adjusting for age, age2, sex, region, array type, and the first 12 genetic principal components, there were no significant associations of three tea consumption variables with the incidence of cancer and cancer subtypes. Compared with non-daily tea drinkers, the HR (95%CI) of daily tea drinkers for cancer and some subtypes, including stomach cancer, liver and intrahepatic bile ducts cancer, colorectal cancer, tracheobronchial and lung cancer, and female breast cancer, are respectively 0.99 (0.78-1.26), 1.17 (0.58-2.36), 0.86 (0.40-1.84), 0.85 (0.42-1.73), 1.39 (0.85-2.26) and 0.63 (0.28-1.38). After controlling the impact of alcohol consumption and performing multiple sensitivity analyses, the results were similar. Conclusion: There is no causal relationship between tea consumption and risk of cancer in population in China.

[Association between tea consumption and all-cause mortality in Chinese adults].

Objective: To investigate the association between tea consumption and the risk of all-cause and cause-specific mortality among Chinese adults. Methods: This study was based on China Kadoorie Biobank (CKB). Tea consumption information was self-reported by participants at baseline. Death was mainly identified by linkage to the death registry system. Cox proportional hazard regression models estimated HR and 95%CI. Results: With a median follow-up of 11.1 years, there were 34 661 deaths in 438 443 participants. Compared with those who never drink tea, all-cause mortality HR(95%CI) were 0.89(0.86-0.91) and 0.92(0.88-0.95) for non-daily tea drinkers and daily tea drinkers, respectively. A statistically significant difference was found in the association of tea consumption and the risk of all-cause mortality between men and women(interaction P<0.05). The protective effect was mainly seen in men. Compared with those who never drink tea, daily tea drinkers had a reduced risk of death from ischemic heart disease, ischemic stroke, hemorrhagic stroke, cancer, respiration diseases and other causes of death, and the corresponding HR(95%CI) were 0.83(0.76-0.92), 0.82(0.69-0.97), 0.86(0.78-0.94), 1.03(0.97-1.09), 1.00(0.87-1.16), 0.84(0.78-0.90). Among never smokers and non-excessive drinkers, there was no statistically significant association between daily tea drinking and the risk of death from cancer. While smokers and excessive drinkers had an increased risk of death from cancer (interaction P<0.001). Conclusions: Tea consumers had reduced risks of all-cause mortality and partial cause-specific mortality, but not for the risk of death from cancer. On the contrary, daily tea drinkers with smoking habits and excessive alcohol drinking had an increased risk of death from cancer.

[Detection of clinical diagnosis and different symptoms of Sjogren's syndrome by traditional chinese medicine (TCM)]

OBJECTIVE:To search for the appropriate diagnostic criteria of SS and confirm the differentiation of SS.METHODS:The European di agnostic criteria has been used in clinic work for about two years,and differentiated the symptoms of SS by TCM. The specialty and relationship between them was made an inquiry.RESULTS:The European criteria set for SS offers the clinic work a practical method to correctly classify the patients suspected of having this disorder. It refers to the signs and symptoms caused by the insufficiency of spleen-qi with deficiency of liver-yin and kidney-yin.CONCLUSION:It has been further proved for easy to make up the diagnostic of SS and its treatment using traditional chinese medicine.

[Experimental research on animal model and treatment of Sjogren's syndrome by traditional chinese medicine (TCM)]

OBJECTIVE:To confirm the function of SS Syrup used in our department. METHODS: Under the basis of TCM and differentiation symptoms of SS,the animal model was established and applied to test the function of SS syrup.There are three indices to be observed,weight change,volume of drinking water daily,cAMP change. RESULTS: The three observed indices of dificiency symptom model had been rectified by SS syrup. CONCLUSION: SS syrup has two main functions:(1)reinforcing of the spleen and tonifying qi;(2)nourishing liver-yin and kidney-yin as well as removing pathogentic heat and fire.

[Effect of nei-yi recipe on plasma beta-endorphin levels during menstrual cycle in women with endometriosis].

In order to investigate the mechanism of Nei-Yi Recipe (NYR) in treatment of endometriosis, we observe the changes of plasma beta-endorphin concentrations in women with endometriosis treated by NYR. It was found that in luteal phase beta-endorphin concentrations in plasma were significantly reduced in moderate and severe dysmenorrhea groups compared with mild and control groups. Moreover, beta-endorphin level in severe dysmenorrhea group was lower in the luteal phase than that in the follicular phase, and it was lower in patients with pelvic pain than that without pelvic pain. In normal women, the contents of beta-endorphin in plasma were not changed during menstrual cycle. It was also found that plasma beta-endorphin levels were significantly increased in luteal phase and follicular phase after treatment by NYR. The therapeutical mechanism of NYR on dysmenorrhea and pelvic pain and enhancement of immune function might be mediated by increase of plasma beta-endorphin levels.

[Effect of endometriosis pill No. 2 on beta-endorphin and dynorphin in endometriosis].

In order to explore the correlation between endometriosis and beta-Endorphin, Dynorphin, the beta-Endorphin and Dynorphin levels in menstrual blood of normal women and patients with endometriosis, and the pituitary-hypothalamic beta-Endorphin and Dynorphin levels in animal models were determined. The results indicated: (1) The plasma beta-Endorphin and Dynorphin levels in patients with endometriosis were significantly lower than those in normal women (P < 0.05); the plasma beta-Endorphin levels in patients with endometriosis were significantly higher after treatment of Endometriosis Pill No. 2 (P < 0.05). (2) The pituitary and hypothalamic beta-Endorphin levels in untreated group were significantly higher than those in the control group (P < 0.05); the hypothalamic beta-Endorphin in treated group were obviously higher than those in untreated group (108.35 +/- 35.38 and 66.63 +/- 14.29 respectively). The above-mentioned results presented evidence that the low beta-Endorphin and Dynorphin levels in endometriotic patients play a role in dysmenorrhea; the effect of Endometriosis Pill No. 2 in relieving dysmenorrhea was realized through an increase of plasma and hypothalamic beta-Endorphin levels. (3) The Pituitary and hypothalamic beta-Endorphin levels were significantly different between the animal models of endometriosis and normal control groups.